Duke-NUS and T Cells Diagnostics team up to simplify T-cell analysis
Virus-specific T-cell measurement is made easier to enable better understanding of immune responses in patients and management of human infectious diseases.
SINGAPORE, April 17, 2025 /PRNewswire/ -- T Cell Diagnostics Pte. Ltd. ("TCD") has licensed an intellectual property (IP) and its related know-how from Duke-NUS Medical School to develop point-of-care assays that could simplify the analysis of T-cell responses.
Point-of-care tests can be performed quickly and easily at the site of patient care, such as in clinics or hospitals, without the need of specialised lab equipment. They provide rapid results, helping doctors and researchers make timely decisions.
TCD was established in Singapore in 2021 as a spin-off from Duke-NUS by Professor Antonio Bertoletti, Assistant Professors Nina Le Bert and Anthony Tan from Duke-NUS' Emerging Infectious Diseases Programme. Developed based on the licensed IP and its related know-how, TCD's test kits precisely measure the amount of virus-specific T cells in clinical samples by stimulating biological samples—ranging from whole blood to nasal swabs and bronchoalveolar lavage fluids—with synthetic peptides. In response to the stimulation, the T cells release chemical signals called cytokines, which can be easily measured.
Assistant Professor Nina Le Bert, who is currently applying this technology in her research on samples from patients chronically infected with the Hepatitis B Virus, said: "We are impressed by the simplicity and performance of the test kit, which has allowed the testing of hundreds of patient samples with ease and precision. It is heartening to see that the interest in measuring T-cell responses induced by vaccination or infection is gaining traction as such knowledge empowers healthcare providers and researchers to better understand immune responses in patients, in turn driving innovations to improve patient care."
Mr Alessandro Sidoli, CEO of T Cell Diagnostics: "We are confident that the addition of this technology to our portfolio is a major step towards achieving our goal of using T cells as a diagnostic. Our team combines deep scientific expertise with a commitment to delivering reliable, high-quality results, ensuring that our partners can confidently advance their research and clinical goals. Whether you're exploring immune responses to viral infections, vaccination, or even cancer, TCD is your trusted partner in unlocking the power of T cell immunity."
TCD offers end-to-end solutions, including project management, expert consultations, and advanced research testing services. The main focus is on analysing virus-specific cellular immune responses, with a particular emphasis on infections such as HBV, HDV, Influenza, SARS-CoV-2, and Dengue.
By quantifying the number and function of antigen-specific T cells, TCD provides critical insights that can guide diagnosis, treatment, and vaccine development. Operating from a state-of-the-art BSL-2 laboratory in Singapore's Biopolis, TCD is strategically positioned to serve local, regional, and international clients.
Associate Professor Christopher Laing, Vice-Dean for Innovation and Entrepreneurship at Duke-NUS, said: "Innovation in science is not just about discovery—it's about turning knowledge into solutions that improve lives. Duke-NUS scientists are among the most entrepreneurial in Asia, and our culture of innovation is supportive of partnering with startups. Our collaboration with TCD exemplifies Duke-NUS' commitment to bridging academia and industry, accelerating groundbreaking discoveries from universities to patients and society."
About Duke-NUS Medical School
Duke-NUS is Singapore's flagship graduate entry medical school, established in 2005 with a strategic, government-led partnership between two world-class institutions: Duke University School of Medicine and the National University of Singapore (NUS). Through an innovative curriculum, students at Duke-NUS are nurtured to become multi-faceted 'Clinicians Plus' poised to steer the healthcare and biomedical ecosystem in Singapore and beyond. A leader in ground-breaking research and translational innovation, Duke-NUS has gained international renown through its five signature research programmes and 10 centres. The enduring impact of its discoveries is amplified by its successful Academic Medicine partnership with Singapore Health Services (SingHealth), Singapore's largest healthcare group. This strategic alliance has spawned 15 Academic Clinical Programmes, which harness multi-disciplinary research and education to transform medicine and improve lives.
For more information, please visit www.duke-nus.edu.sg
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/duke-nus-and-t-cells-diagnostics-team-up-to-simplify-t-cell-analysis-302431130.html
SOURCE Duke-NUS Medical School
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
AstriVax Therapeutics Initiates Clinical Development of AVX70371, a Hepatitis B immunotherapy using Launch-iT technology
Third asset to advance into clinical trials, validating broad potential of Launch-iT platform All subjects treated with first dose of AVX70371 Launch-iT, as part of multiple dosing schedule Potential first-in-class treatment that could form part of functional cure for over 250 million patients suffering from chronic hepatitis B virus (HBV) infection Leuven, Belgium, June 5, 2025 – AstriVax Therapeutics NV, a clinical stage immunotherapy company developing novel treatments for chronic infections based on its proprietary Launch-iT technology, announced today the start of clinical development with AVX70371 for chronic hepatitis B virus (HBV) infection. The phase I RUBY study (NCT06989788) will evaluate the safety, tolerability and immunogenicity of repeated injections of AVX70371 in 16 healthy adult volunteers at the Centre for Vaccinology of the Ghent University, Belgium. Up to three doses of AVX70371 are being evaluated in preparation for an assessment in a chronic HBV patient population, who are known to experience HBV-specific immune exhaustion. All subjects have now been treated with the first dose of AVX70371. The trial is expected to be completed in the second half of 2026, with an interim analysis before the end of 2025. 'AVX70371 has been designed to elicit a specific T-cell immune response against infected hepatocytes in which HBV is actively replicating. Knowing that patients with chronic hepatitis B suffer from immune exhaustion, this targeted immunotherapy approach is expected to intervene at the source of the chronic viral infection,' said Mathieu Peeters, M.D., Chief Development Officer at AstriVax Therapeutics. 'Starting clinical development with AVX70371 is the first step in the development of a new approach that could form the basis of a functional cure for chronic HBV infection.' 'Following positive results from our first clinical study in 2024, which evaluated the safety and immunogenicity of our Launch-iT technology platform, starting the clinical development with our first therapeutic Launch-iT program is a significant milestone for AstriVax Therapeutics. Despite available preventive vaccines, chronic hepatitis B still affects over 250 million people worldwide, so there is an ongoing need for improved options for patients beyond life-long antiviral treatment,' Hanne Callewaert, Ph.D., co-founder and CEO of AstriVax Therapeutics, added. 'AstriVax Therapeutics is also in the process of selecting a second immunotherapy Launch-iT clinical candidate for treating human papilloma virus (HPV) infection. Our plan is to rapidly advance this program towards clinical development in patients, further supporting our track record of moving assets quickly into the clinical validation phase.' About Launch-iTLaunch-iT (launched Immnunotherapy) is a plasmid-based technology that can rapidly generate viral vectors encoding novel antigens of interest as immunotherapy drug candidates. The tolerability and effectiveness of the platform has been validated in the SAFYR clinical study, which demonstrated that a single injection with AVX70120 (Yellow fever) or AVX70481 (Rabies) is very well tolerated and can induce high and long-lasting antibody titers and T-cell counts including CD4 and CD8 T-cells. About AstriVax TherapeuticsAstriVax Therapeutics is a clinical stage biopharmaceutical company developing novel immunotherapies that could offer broad and long-lasting treatment of chronic infectious diseases. Leveraging its proprietary Launch-iT plug and play plasmid-based technology, AstriVax Therapeutics is building a portfolio of product candidates targeting chronic viral infections, initially focused on hepatitis B virus (HBV) and human papilloma virus (HPV) infections. The company's Launch-iT product candidates are potential game-changers in the fight against viral pathogens. They are easy to produce, have limited cold chain requirements, and are expected to trigger a strong and lasting immune response. AstriVax Therapeutics is supported by well-known investors V-Bio Ventures, Fund+, Flanders Future TechFund managed by PMV, Thuja Capital, Ackermans & van Haaren, OMX Europe Venture Fund (Mérieux Equity Partners and Korys), BNP Paribas Fortis Private Equity, and the KU Leuven Gemma Frisius Fund. Founded in 2022, AstriVax Therapeutics is located in Leuven, Belgium. For more information, please visit Media contacts:Hanne Callewaert, PhD, CEO of Astrivax Therapeuticscorporate@ Alexandra SchiettekatteTel: +32 476 65 04 38alexandra@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
a day ago
- Medscape
Social Withdrawal in Aging Tied to Shifts in Brain Networks
There is a natural decline in sociability as a result of aging influenced by brain changes, new research shows. 'Our study suggests that age-related changes in the functional wiring of the brain may impair certain abilities needed to maintain social relationships,' the study's lead study author Yuet Ruh Dan, Duke-National University of Singapore Medical School, told Medscape Medical News . The findings were published online on May 28 in PLOS One . Sociability Critical to Health Sociability, which is the capacity to communicate effectively, be socially assertive, and to manage emotions, is 'critical' for maintaining and promoting health, especially as we age, said Dan. Research has linked sociability to increased functional connectivity in and between intrinsic brain networks. Overall, the default mode network (DMN), ventral attention network, and limbic structures have been the most strongly correlated with sociability. The aging process also involves changes in intrinsic brain networks. Studies have shown that aging results in lower within-network connectivity, as well as greater between-network connectivity. For example, Dan noted that connectivity between the frontoparietal and DMNs decreases with age change that has been linked to poorer self-esteem and memory. Meanwhile, connectivity between the limbic and insular regions increases with age and has been shown to activate in situations involving social exclusion, she added. 'Intuitively, poorer self-esteem and an increased sensitivity to exclusion may be linked to a decreased ability to communicate with others and regulate our emotions,' she said. This study is among the first — if not thefirst — to directly examine the relationship between age-related changes in functional connectivity and sociability, Dan added. The study included 196 healthy participants aged 20-77 years (mean age, approximately 38 years), with 34.2% identifying as female, drawn from the Leipzig Study for Mind-Body-Emotion Interactions dataset. For the analysis, researchers grouped participants into 5-year age brackets (20-25, 25-30, etc.), Dan said. In addition, the researchers obtained resting-state functional MRI data. Participants completed the sociability subscale of the Trait Emotional Intelligence Questionnaire Short Form. This six-question subscale measures social awareness, emotional management, communication effectiveness, and participation in social situations. The questionnaire is scored on a 7-point Likert scale ranging from 1 (completely disagree) to 7 (completely agree), with higher scores indicating higher levels of sociability. Researchers also collected data using the NEO Five-Factor Inventory (NEO-FFI), which measures neuroticism, extraversion, openness to new experiences, agreeableness, and conscientiousness. They found a strong positive correlation between sociability and extraversion ( P < .001), highlighting a significant link between the two traits. Researchers conducted network-based analyses to identify patterns of resting-state functional connectivity, grouping the data into an age-positive network (APN), which showed a positive correlation with age, and an age-negative network (ANN), which showed a negative correlation. 'Essentially, we found that with increased age, there is a group of functional brain networks that become more interconnected and a group that becomes less interconnected,' said Dan. The subcortical-parietal connectivity and the within-limbic connectivity were the most negatively correlated in the ANN, while limbic-insular connectivity was the strongest positive correlation within the APN. Within the positive connectivity network, ventral attention-somatomotor connectivity had the strongest correlation with age. Frontoparietal-DMN connectivity was the most negatively correlated with age. Decreased Connectivity, Sociability Both ANN and APN may contribute to decreased sociability, but it's not yet clear which plays the more dominant role, Dan said. However, she and her colleagues have some theories. They propose that reduced connectivity between the frontoparietal and DMN regions may be linked to impaired cognition and lower self-esteem, 'thereby resulting in impaired social assertiveness, emotional regulation skills, and reduced sociability.' Decreased connectivity of these regions could be linked to decreased sociability through impaired executive processing, they noted. The study illustrates that as we age, 'it may not be just a lack of social contact opportunities that prevents us from forming and maintaining relationships but also an inherent change in the brain's functional wiring,' Dan said. A mediation analysis showed the effect of age on sociability was fully mediated via both APN and AAN. 'Generally, these statistical results meant that the networks that become more connected, for example APN, as well as less connected, for example, ANN, with age can explain decreased sociability seen across the lifespan,' said Dan. Dan emphasized that sociability is just one factor related to loneliness — and one that is relatively easy to measure — whereas loneliness itself is a far more complex and deeply subjective experience. 'Intuitively, people with lower sociability scores may be more likely to be lonely, as they may find it harder to maintain relationships. In this sense, increased sociability may be a risk factor for increased loneliness with age.' Dan said she hopes these preliminary findings will spur more longitudinal research into these relationships and help inform efforts to support healthy aging. She noted the importance of physicians recognizing that declining sociability may be a natural part of aging. 'Greater emphasis should be placed on community-based health promotion efforts,' she said. The investigators did not analyze NEO-FFI personality trait variables, so 'we can't draw any conclusions about whether they were related to changes in brain connectivity or sociability,' Dan said. She also noted that the sample was heavily skewed toward younger participants, which may limit the reliability of the findings for older adults. Additionally, grouping subjects into 5-year age bins may have introduced 'noise' into the statistical models. Other limitations included an all-European study sample, and collection of sociability data exclusively via self-report, which may be less reliable than more objective measures like social network size. Interpret With Caution Commenting for Medscape Medical News , Dirk Scheele, PhD, professor of social neuroscience, Ruhr University Bochum, Bochum, German, said the paper addresses a 'relevant' topic. 'The general question of how social interactions and the desire for social engagement change with age is undoubtedly important, particularly given strong evidence that the risk of social isolation and loneliness increases with advancing age,' he said. However, the underlying neural mechanisms remain 'surprisingly unclear,' he said. 'For example, no study to date has directly compared the neural substrates of loneliness or social isolation between younger and older adults.' Although the study 'has the potential to inspire novel research questions,' its findings should be interpreted with 'considerable caution' due to several limitations, he said. 'Most notably, it's an entirely exploratory study without preregistration, and its cross-sectional design prevents conclusions about causal relationships,' he added. Scheele also noted the 'sociability' construct was derived from a subscale of a questionnaire and 'encompasses multiple facets, such as emotion regulation and social awareness, that may belinked to distinct neural mechanisms.'
News24
2 days ago
- News24
Myths and misconceptions about the medical marvel that is the flu vaccine
In 1918, a particularly virulent strain of influenza is estimated to have infected 500 million people worldwide, killing between 20 and 50 million people, and causing more fatalities than the entire course of the First World War1. It was not until the 1930s, and after many years of deadly influenza pandemics, that influenza was identified to be caused by a virus and not a bacterial infection, a vital step towards developing an effective vaccine1. Historically, as each new vaccine proved effective in a particular flu season, the following season would see scientists discovering that some patients were not developing the necessary antibodies to the identified strain, which led to the discovery of different influenza strains1. Fortunately today, scientists now manufacture vaccines based on the monitoring of virus strains in circulation around the world, updating the strains targeted by the vaccine in response1. According to the World Health Organisation (WHO), the flu vaccine is still the best way to prevent the flu2. Flu viruses mutate very rapidly, and as the viruses spread, many different strains develop, which fall into 2 main types namely influenza A and influenza B11. Because flu viruses are constantly evolving, flu vaccines are updated from one season to the next to protect against the viruses that research suggests will be common during the upcoming flu season3. For the past few years, a quadrivalent influenza vaccine has been available worldwide to protect against four different flu viruses, including two influenza A viruses and two influenza B viruses4. However, given that there have not been any confirmed detections of the one influenza B virus since March 2020, the World Health Organization Flu Vaccine Strain-Selection Committee has recommended switching back to trivalent (three-strain) vaccines that include two influenza A strains plus just the one influenza B strain5. This vaccine will be available in South Africa this month. Despite over 60 years of medical research, clinical trials and proven safety and efficacy, as well as the fact that the flu vaccine can reduce the chances of getting sick by up to 60%, many myths and misconceptions about the potentially life saving medical intervention still exist6,7. Flu isn't serious Many people are still under the impression that flu isn't serious. According to the National Institute for Communicable Diseases, seasonal flu results in between 6 000 and 11 000 deaths in South Africa annually, as a result of flu complications. People who are more at risk of severe flu complications include the elderly, pregnant women and those with chronic illnesses such as diabetes, lung disease, tuberculosis and heart disease8. The flu vaccine causes flu One common myth that exists is that the flu vaccine can cause flu. This is not true. To cause an infection, a flu virus needs to reproduce, and no flu vaccine anywhere in the world contains viruses that can reproduce. Some people may feel some minor side effects after being vaccinated, including slight fever, aches, or fatigue, but these can all be normal signs that your immune system is learning to fight off the flu6. One vaccine every few years should suffice Some people think that the flu vaccine they had last year will protect them again the following year. Unlike other vaccines, flu vaccines are not intended to last longer than one year. This is because flu viruses are constantly changing, and flu vaccines are updated from one season to the next6. Flu vaccines are dangerous for pregnant women On the contrary, pregnant women are a higher risk group who should get the flu vaccine, since their immune systems are weaker than usual. The inactivated flu vaccine is safe at any stage of pregnancy5. Flu vaccines are painful While the thought of a needle might make some people nervous or uncomfortable, medical innovation has also advanced when it comes to administering the flu vaccination. A smart syringe, which is available in South Africa, is one example, which has been designed for precise dosing and injection site comfort9. This is particularly helpful given that the World Health Organisation recommends that children from the age of six months old should get an annual flu vaccination2. Speak to your doctor, pharmacist or local clinic about getting your flu vaccination as soon as possible. It is quick, easy and safe6,7,9 and can protect you and your family from becoming seriously ill with flu, and limits the spread of infection to family, friends and colleagues. References: 1. World Health Organization. History of the Influenza Vaccination (2024) at (website accessed on 18 February 2024) 2. World Health Organization. Key Facts (2023) at (website accessed on 30 January 2024) 3. Centers for Disease Control and Prevention. A Strong Defence Against Flu – Get Vaccinated! (2020) at (website accessed on 30 January 2024). 4. Centers for Disease Control and Prevention Quadrivalent Influenza Vaccine (2023) at (website accessed on 19 February 2024) 5. University of Minnesota. WHO advisers recommend switch back to trivalent flu vaccines (2023) at (website accessed on 19 February 2024) 6. Families Fighting Flu Inc. Facts on Flu Vaccines (2021) at (website accessed on 18 February 2024) 7. World Health Organization. 5 Myths about the Flu Vaccine (2024) at (website accessed on 18 February 2024) 8. National Institute for Communicable Diseases. Influenza Season Approaching (2018) at (website accessed on 30 January 2024 9. Smart Syringe System data on file
